论文部分内容阅读
目的探讨卵巢癌肿瘤抗原新基因OCY-142即BARD1的剪切变异体在卵巢癌中的表达及临床意义。方法用RT-PCR的方法检测OCY-142在卵巢癌组织和正常卵巢组织中的表达。结果在28例卵巢癌组织中,有10例(35.7%)明显表达OCY-142抗原基因,而30例正常卵巢组织中均没有OCY-142抗原基因的表达,两者之间有显著性差异(P<0.05)。OCY-142的表达与卵巢癌的病理类型有关,在浆液性乳头状囊腺癌患者中有较高的特异性(P<0.05),但OCY-142的表达与卵巢癌的临床分期和组织分化程度没有相关性(P>0.05)。结论卵巢癌肿瘤抗原基因OCY-142是BARD1基因的1个剪切变异体,其有可能成为卵巢恶性肿瘤免疫治疗的新靶点。OCY-142在卵巢浆液性囊腺癌中有较高的表达,其临床意义值得进行更深入的研究。
Objective To investigate the expression and clinical significance of ovine cancer tumor antigen OCY-142, a variant of BARD1, in ovarian cancer. Methods The expression of OCY-142 in ovarian cancer tissues and normal ovarian tissues was detected by RT-PCR. Results Of the 28 cases of ovarian cancer, 10 (35.7%) expressed OCY-142 antigen gene, while none of the 30 cases of normal ovarian tissue expressed OCY-142 antigen gene, with significant difference between the two P <0.05). The expression of OCY-142 is correlated with the pathological type of ovarian cancer, and is highly specific in patients with serous papillary cystadenocarcinoma (P <0.05). However, the expression of OCY-142 is related to the clinical stage and differentiation of ovarian cancer The degree was not related (P> 0.05). Conclusions OCY-142, an ovarian cancer tumor antigen gene, is a shearing variant of BARD1 gene, which may be a new target for immunotherapy of ovarian cancer. OCY-142 in ovarian serous cystadenocarcinoma has a higher expression, its clinical significance deserves more in-depth study.